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Abstract
Background. An accurate pre-therapeutic assessment of the resectability in pancreatic cancer patients is essential to
reduce the number of futile surgical explorations. The aim of this study was to assess the combination of endoscopic
ultrasound (EUS) and laparoscopic ultrasound (LUS) regarding the detection of patients with non-resectable
tumours. Patients and methods. From 2002 to 2004, 179 consecutive patients with pancreatic cancer referred for surgical
treatment were eligible. Thirty-one (17%) patients were excluded due to co-morbidity and poor performance status. Two
patients (1%) were excluded due to metastasis seen on CT scans prior to referral. Thus, 146 patients entered the study.
Patients were first examined with EUS followed by LUS, if EUS found no signs of non-resectability. Only patients with
tumours found to be resectable or possibly resectable at EUS and LUS were offered surgical treatment. Resectability criteria
were defined prior to the study. Results. In all, 108 (74%) patients had non-resectable tumours by the pre-defined criteria.
EUS identified 68 (63%) patients and LUS identified an additional 26 (24%) patients. Thus, a total of 94 (87%) patients
were non-resectable at either EUS or LUS. Fifty-two (36%) patients underwent surgery. Six patients had surgical
exploration and three patients had palliative surgery. Forty-three patients (29%) were resected with curative intention, of
whom 38 (88%) had an R0 resection and 5 (12%) had a palliative resection. Discussion. The combination of EUS and LUS
is accurate in identifying the non-resectable patients and has a high predictive value for complete resection.
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Introduction
Pancreatic cancer is often diagnosed in an advanced
stage. Radical surgery is the only curative treatment,
but even after complete resection the overall prognosis
is poor [1/3]. Surgery carries a significant morbidity
and mortality[4/6], and as extended surgery may
not improve outcome, careful selection of patients
for surgery is necessary to avoid futile explorations
[7,8]. Several imaging modalities have been shown to
be of value in staging of pancreatic cancer [9/14], but
no single modality has a high predictive value for
complete resection. The combination of endoscopic
and laparoscopic ultrasound (EUS and LUS)
has been shown to be a cost-effective strategy for
patients with non-resectable upper gastrointestinal
tumours [15].
The aim of this study was to evaluate the combina-
tion of EUS and LUS in the preoperative assessment
of patients with pancreatic cancer. The major end
points of the evaluation were the predictive value for
complete resection (R0 resection) and the number of
futile explorative laparotomies.
Materials and methods
All patients with histologically verified carcinoma of
the pancreas referred to the Department of Surgical
Gastroenterology, Odense University Hospital, in the
period from 1 January 2002 to 29 February 2004 were
included. All patients had either CT or abdominal
ultrasound as initial examination before referral.
Patients with known metastasis or non-resectability
from prior CT or ultrasound were excluded. Patients
with poor performance status and re-evaluation after
down-staging with chemo-radiotherapy were also
excluded.
The evaluation strategy is shown in Figure 1.
Patients with local tumour infiltration of the portal
vein, superior mesenteric vessels, coeliac trunk and
transverse mesocolon were considered non-resectable.
Patients with carcinosis, non-regional lymph nodes
and liver metastasis were considered incurable. Re-
gional metastatic lymph nodes were not considered as
non-resectability. All metastatic lesions were histolo-
gically verified by fine needle aspiration. Using these
criteria, EUS and LUS designated each patient into
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one of three groups: (1) resectable, (2) possibly
resectable and (3) non-resectable. Patients in groups
1 and 2 would proceed to LUS and possibly surgery,
whereas patients in group 3 would be discussed with
the oncologists. Patients in group 1 would be sched-
uled for both LUS and resection on the same day.
Patients designated to group 2 by EUS had LUS
performed as a separate procedure, as it was expected
that only a small proportion of these patients were
actually resectable.
Surgical bypass was only offered to patients, where
endoscopic (or radiological) palliation failed.
All examinations were prospectively registered.
EUS was performed by surgeons with a wide experi-
ence in endosonography (/300 staging procedures
performed prior to the study). Likewise, LUS was
performed by experienced surgeons (/100 staging
procedures).
Statistics
For categorical data Fisher’s exact test was used.
p valuesB/0.05 were considered significant. Confi-
dence intervals (CI) are reported as 95%.
Results
A total of 179 patients were referred in the study
period. Of these, 82 (46%) were women and 97 (54%)
males, with a median age of 66 years (range 22/89).
Of the 179 patients, 31 (17%) were not fit for surgery
due to poor performance status and were excluded. In
two (1%) patients initial CT scans revealed liver
metastases, the patients were referred for biopsy
only, and both were excluded from the study. Thus,
146 patients entered the study. The results of EUS,
LUS and surgery are shown in Figure 2, and the
reason(s) for non-resectability are shown in Table I.
There were no complications after EUS or LUS.
A total of 108 patients were found to be non-
resectable, 68 by EUS, 26 by LUS and 14 at surgery.
The combined preoperative assessment identified 94
(87%, CI 79/93%) of the non-resectable patients. Of
the 108 non-resectable patients 3 patients underwent
R0 resection after down-staging with chemo-radio-
therapy.
EUS found 51 patients to be resectable (group 1),
of these 32 (63%) underwent an R0 resection. In
comparison EUS found 24 to be possibly resectable
(group 2) and of these only 4 (17%) underwent an R0
resection (pB/0.01). In three (2%) patients EUS was
not possible.
Following laparoscopy and LUS an additional
26 non-resectable tumours were found. Thus, 52
patients were scheduled for resection. Of these 38
(73% CI 59/84%) patients had an R0 resection, five
(10%) patients had an R1 or R2 resection, three (6%)
patients had a surgical bypass and six (12%) patients
had a futile explorative laparotomy.
Discussion
With EUS as first examination 47% of the patients
could be classified as non-resectable and avoid further
examination(s). Laparoscopic staging found non-re-
sectable tumours in 33% of the remaining patients.
This is comparable to other studies [9/11,16],
although one study reported a very low effect of
laparoscopic staging [17]. However, this study may be
biased as biopsy to prove non-resectability during
LUS was required, whereas the normal staging with
CT did not include biopsy to prove non-resectability.
Vascular invasion is difficult to prove with biopsy with
any imaging modality, and even at surgery it can be
difficult to assess whether there is tumour infiltration
or just tumour adhesion or inflammation [7].
One limitation of the present study with regard to
local non-resectability is the lack of histopathological
proof of non-resectability. From resections of the
portal and superior mesenteric vein it has been shown
that only in 57% of patients with suspected infiltration
is there histopathological evidence of tumour infiltra-
tion [7]. However, the criteria used for non-resect-
ability have proved to be accurate, and other studies
have shown only very few over-staged patients using
this approach [10,11,13,18,19].
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Figure 1. Preoperative assessment strategy. Non-resectable patients were referred for oncological evaluation. EUS, endoscopic ultrasound;
LUS, laparoscopic ultrasound.
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The predictive value for R0 resection was 73%, but
with a wide confidence interval due to the small
number of resections. A recent study using solely CT
as preoperative staging showed a predictive value of
44% (CI 39/49%) [2], and a large study of CT and
LUS as staging strategy showed a predictive value for
R0 resection of 62% (CI 56/69%) [17].
One of the main differences between studies is the
number of patients treated with surgical bypass. In
our study only three patients could not be managed
with endoscopic palliation alone. However, if surgical
bypass is widely used, the impact of any preoperative
assessment will be low, as a high proportion of
patients will require laparotomy regardless of the
assessment. The choice between surgical and endo-
scopic palliation has long been debated [20/26].
Endoscopic palliation has a higher rate of re-inter-
vention, but shorter hospital stay and lower morbidity.
As patients with non-resectable pancreatic cancer
have a very short life expectancy, we find the endo-
scopic palliation to be more attractive, even if it
requires more re-interventions. Thus, the impact of
EUS and LUS is high with regard to avoiding
unnecessary surgical explorations. We found only
12% futile laparotomies when using EUS and LUS
in a combined strategy.
In conclusion the combination of EUS and LUS as
preoperative assessment for patients with pancreatic
cancer is efficient in identifying the non-resectable
patients and has a high predictive value for complete
resection.
References
[1] Smeenk HG, Tran TC, Erdmann J, van Eijck CH, Jeekel J.
Survival after surgical management of pancreatic adenocarci-
noma: does curative and radical surgery truly exist? Langen-
becks. Arch Surg 2005;/390:/94/103.
Table I. Number of patients with non-resectable tumours and
reason(s) for non-resectability.
Liver metastasis 12
EUS (n/68) Tumour infiltration and metastasis 13
Local tumour infiltration 43
Local tumour infiltration 1
Laparoscopy (n/9) Carcinosis 3
Liver metastasis 5
LUS (n/17) Liver metastasis 4
Local tumour infiltration 13
Pancreatic Carcinoma
N=179
EUS
N=146, *2
Not fit for surgery
N=31
Metastasis on CT
N=2, *1
Laparoscopy + LUS
N=78, *3
Non-resectable
N=68
Surgery
N=52
Non-resectable
N=26
Exploration
N=6
Surgical bypass
N=3
Resection
N=43
R0-resection
N=38
R1-resection
N=3
R2-resection
N=2
Figure 2. Evaluation results. *1, two patients with known metastasis referred for biopsy; *2, in three patients EUS could not be completed;
*3, in five patients LUS was not possible due to adhesions.
Preoperative assessment of pancreatic cancer 59
[2] Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler
MW. Curative resection is the single most important factor
determining outcome in patients with pancreatic adenocarci-
noma. Br J Surg 2004;/91:/586/94.
[3] Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S,
Abrams RA, et al. Resected adenocarcinoma of the pancreas /
616 patients: results, outcomes, and prognostic indicators. J
Gastrointest Surg 2000;/4:/567/79.
[4] Behrman SW, Rush BT, Dilawari RA. A modern analysis of
morbidity after pancreatic resection. Am Surg 2004;/70:/675/
82.
[5] Tran KT, Smeenk HG, van Eijck CH, Kazemier G, Hop WC,
Greve JW, et al. Pylorus preserving pancreaticoduodenectomy
versus standard Whipple procedure: a prospective, rando-
mized, multicenter analysis of 170 patients with pancreatic
and periampullary tumors. Ann Surg 2004;/240:/738/45.
[6] Stephens J, Kuhn J, O’Brien J, Preskitt J, Derrick H, Fisher T,
et al. Surgical morbidity, mortality, and long-term survival in
patients with peripancreatic cancer following pancreaticoduo-
denectomy. Am J Surg 1997;/174:/600/3.
[7] Beger HG, Rau B, Gansauge F, Poch B, Link KH. Treatment
of pancreatic cancer: challenge of the facts. World J Surg 2003;/
27:/1075/84.
[8] Schafer M, Mullhaupt B, Clavien PA. Evidence-based pan-
creatic head resection for pancreatic cancer and chronic
pancreatitis. Ann Surg 2002;/236:/137/48.
[9] Durup Scheel-Hincke J, Mortensen MB, Qvist N, Hovendal
CP. TNM staging and assessment of resectability of pancreatic
cancer by laparoscopic ultrasonography. Surg Endosc 1999;/
13:/967/71.
[10] Menack MJ, Spitz JD, Arregui ME. Staging of pancreatic and
ampullary cancers for resectability using laparoscopy with
laparoscopic ultrasound. Surg Endosc 2001;/15:/1129/34.
[11] Mortensen MB, Scheel-Hincke JD, Madsen MR, Qvist N,
Hovendal C. Combined endoscopic ultrasonography and
laparoscopic ultrasonography in the pretherapeutic assessment
of resectability in patients with upper gastrointestinal malig-
nancies. Scand J Gastroenterol 1996;/31:/1115/9.
[12] Santo E. Pancreatic cancer imaging: which method? JOP
2004;/5:/253/7.
[13] Soriano A, Castells A, Ayuso C, Ayuso JR, de Caralt MT,
Gines MA, et al. Preoperative staging and tumor resectability
assessment of pancreatic cancer: prospective study comparing
endoscopic ultrasonography, helical computed tomography,
magnetic resonance imaging, and angiography. Am J Gastro-
enterol 2004;/99:/492/501.
[14] Alexakis N, Halloran C, Raraty M, Ghaneh P, Sutton R,
Neoptolemos JP. Current standards of surgery for pancreatic
cancer. Br J Surg 2004;/91:/1410/27.
[15] Mortensen MB, Ainsworth AP, Langkilde LK, Scheel-Hincke
JD, Pless T, Hovendal C. Cost-effectiveness of different
diagnostic strategies in patients with nonresectable upper
gastrointestinal tract malignancies. Surg Endosc 2000;/14:/
278/81.
[16] John TG, Greig JD, Carter DC, Garden OJ. Carcinoma of the
pancreatic head and periampullary region. Tumor staging with
laparoscopy and laparoscopic ultrasonography. Ann Surg
1995;/221:/156/64.
[17] Nieveen van Dijkum EJ, Romijn MG, Terwee CB, de Wit LT,
van der Meulen JH, Lameris HS, et al. Laparoscopic staging
and subsequent palliation in patients with peripancreatic
carcinoma. Ann Surg 2003;/237:/66/73.
[18] Ahmad NA, Kochman ML, Lewis JD, Kadish S, Morris JB,
Rosato EF, et al. Endosonography is superior to angiography
in the preoperative assessment of vascular involvement among
patients with pancreatic carcinoma. J Clin Gastroenterol 2001;/
32:/54/8.
[19] Durup J. TNM staging and assessment of resectability in
esophageal, gastric, and pancreatic cancer patients using
laparoscopic ultrasonography (LUS). PhD thesis, University
of Southern Denmark, 2001.
[20] Maosheng D, Ohtsuka T, Ohuchida J, Inoue K, Yokohata K,
Yamaguchi K, et al. Surgical bypass versus metallic stent for
unresectable pancreatic cancer. J Hepatobiliary Pancreat Surg
2001;/8:/367/73.
[21] Wong YT, Brams DM, Munson L, Sanders L, Heiss F, Chase
M, et al. Gastric outlet obstruction secondary to pancreatic
cancer: surgical vs endoscopic palliation. Surg Endosc 2002;/
16:/310/2.
[22] Andersen JR, Sorensen SM, Kruse A, Rokkjaer M, Matzen P.
Randomised trial of endoscopic endoprosthesis versus opera-
tive bypass in malignant obstructive jaundice. Gut 1989;/30:/
1132/5.
[23] Bornman PC, Harries-Jones EP, Tobias R, Van SG, Ter-
blanche J. Prospective controlled trial of transhepatic biliary
endoprosthesis versus bypass surgery for incurable carcinoma
of head of pancreas. Lancet 1986;/1:/69/71.
[24] Smith AC, Dowsett JF, Russell RC, Hatfield AR, Cotton PB.
Randomised trial of endoscopic stenting versus surgical bypass
in malignant low bileduct obstruction. Lancet 1994;/344:/
1655/60.
[25] Lillemoe KD, Cameron JL, Hardacre JM, Sohn TA, Sauter
PK, Coleman J, et al. Is prophylactic gastrojejunostomy
indicated for unresectable periampullary cancer? A prospec-
tive randomized trial. Ann Surg 1999;/230:/322/8.
[26] Espat NJ, Brennan MF, Conlon KC. Patients with laparo-
scopically staged unresectable pancreatic adenocarcinoma do
not require subsequent surgical biliary or gastric bypass. J Am
Coll Surg 1999;/188:/649/55.
60 C.W. Fristrup et al.
